Copellor (Ixekizumab) India — What Hospitals and Dermatologists Need to Know
1. What Is Copellor (Ixekizumab)? Copellor® is the brand name for Ixekizumab, a humanised anti-interleukin-17A (anti-IL-17A) IgG4 monoclonal antibody manufactured by Eli Lilly and Company India Pvt Ltd and approved by the Drugs Controller General of India (DCGI). It is available as an 80mg/mL subcutaneous injection in a pre-filled syringe or auto-injector. Ixekizumab works by […]
The Difference Between a Biosimilar and a Generic — What Hospital Pharmacists Need to Know
In hospital pharmacy conversations across India, two words get used interchangeably more often than they should: generic and biosimilar. Both refer to non-originator versions of existing medicines. Both are generally less expensive than the originator product. And both require regulatory approval before they can be sold. But beyond those surface similarities, the two are fundamentally […]
Why Some Medicines Are Imported Instead of Manufactured in India
Walk into any oncology department at a major Indian hospital and you will find medicines from Germany, the United States, Switzerland, Japan, and the United Kingdom sitting alongside domestically manufactured generics. For most patients and their families, this raises a perfectly reasonable question: why is this medicine coming from abroad? Why isn’t it made here? […]
